Frontlight ResearchEarly access
Alzheimer disease trials in Canada
44 of 58 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleCannabidiol Medication Intervention Trial
- Where
- Calgary, London, Toronto, Whitby
- Age
- 55 years and over
- People
- 40
- Run by
- Sunnybrook Health Sciences Centre
See details and how to joinNCT06014424 - Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
- Where
- Greenfield Park, Halifax, Kelowna, Ottawa, Québec, Richmond, Toronto, Victoriaville
- Age
- 60 years to 85 years
- People
- 586 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06976216 · EU 2025-520746-30-00 - Phase 3Taking peopleScreening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
- Where
- Halifax, Kelowna, London, Montreal, Ottawa, Peterborough, Québec, Richmond, Toronto
- Age
- 50 years to 90 years
- People
- 80,000 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07177352 - No phaseTaking peopleImplementing Brain Health PRO Across Diverse Settings: A Multi-Site Implementation Study
- Where
- Montreal
- Age
- 50 years and over
- People
- 434
- Run by
- Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal
See details and how to joinNCT07935629 - Phase 1Taking peopleA Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
- Where
- Montreal, Toronto
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT05231785 · EU 2023-508363-79-00 - Phase 3WithdrawnOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
- Where
- Calgary, Hamilton, Montreal, Verdun, Whitby
- Age
- 55 years to 90 years
- People
- 1,000 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00 - Phase 2Taking peopleA Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
- Where
- Brampton, Lévis, London, Toronto
- Age
- 55 years to 90 years
- People
- 300 worldwide
- Run by
- MapLight Therapeutics
See details and how to joinNCT06887192 · EU 2024-519820-26-00 - Phase 3Taking peopleA Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
- Where
- Hamilton, London, Toronto, Whitby
- Age
- 55 years to 90 years
- People
- 650 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06937229 · EU 2024-519994-20-00 - No phaseNot yet taking people in CanadaVeech Ketone Ester to Support Brain Energy in Mild Cognitive Impairment and Early Alzheimer's Disease
- Where
- London
- Age
- 21 years and over
- People
- 17
- Run by
- University of Pennsylvania
See details and how to joinNCT06767124 - Phase 1/2Taking peopleTrial of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease or Primary Tauopathies
- Where
- East York, Montreal, Toronto
- Age
- 18 years and over
- People
- 160 worldwide
- Run by
- Arrowhead Pharmaceuticals
See details and how to joinNCT07221344 - Phase 3Taking peopleNabilone for Agitation Blinded Intervention Trial
- Where
- Calgary, Hamilton, London, Ottawa, Toronto, Whitby
- Age
- 55 years and over
- People
- 112
- Run by
- Sunnybrook Health Sciences Centre
See details and how to joinNCT04516057 - Phase 3Taking peopleA Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
- Where
- Hamilton, London, Montreal, Toronto, Whitby
- Age
- 55 years to 90 years
- People
- 426 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07011732 · EU 2025-520613-31-00 - Phase 2/3Taking peopleSafety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
- Where
- North York, Peterborough, Whitby
- Age
- 55 years to 90 years
- People
- 300 worldwide
- Run by
- Exciva GmbH
See details and how to joinNCT07284472 · EU 2024-517388-22-00 - Phase 2Taking peopleA Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
- Where
- Montreal, Ottawa, Toronto
- Age
- 55 years to 85 years
- People
- 160 worldwide
- Run by
- Sanofi
See details and how to joinNCT07688213 · EU 2025-524581-14-00 - Phase 3Taking peopleA Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
- Where
- Kelowna, Montreal, Peterborough, Québec, Toronto
- Age
- 55 years to 80 years
- People
- 1,600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07717411 - No phaseNot yet taking people in CanadaVirtual Reality to Advance Dementia Care and Quality of Life
- Where
- London
- Age
- 55 years and over
- People
- 10
- Run by
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
See details and how to joinNCT07893678 - Phase 2Taking peopleA Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
- Where
- Montreal, Ottawa, Toronto
- Age
- 50 years to 85 years
- People
- 340 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07033494 · EU 2024-519190-19-00 - Phase 3WithdrawnA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
- Where
- Calgary, Hamilton, Montreal, Toronto, Verdun, Whitby
- Age
- 55 years to 90 years
- People
- 500 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06126224 · EU 2023-504416-16-00 - Phase 1Taking peopleA Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
- Where
- Montreal, Ottawa, Toronto
- Age
- 40 years to 80 years
- People
- 50 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT07214727 · EU 2025-522582-30-00 - Phase 1/2WithdrawnClinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
- Where
- Ottawa
- Age
- 40 years to 85 years
- People
- 36 worldwide
- Run by
- NKGen Biotech, Inc.
See details and how to joinNCT06189963 - No phaseTaking peopleENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing
- Where
- Toronto
- People
- 200
- Run by
- Sunnybrook Health Sciences Centre
See details and how to joinNCT04335994 - Phase 2Taking peopleLevetiracetam for Persons at Risk for Alzheimer's Disease
- Where
- Toronto
- Age
- 55 years to 85 years
- People
- 40
- Run by
- Sunnybrook Health Sciences Centre
See details and how to joinNCT07477431 - Phase 2/3Taking peopleA Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
- Where
- Québec, Toronto, Vancouver, Verdun
- Age
- 18 years and over
- People
- 280 worldwide
- Run by
- Washington University School of Medicine
See details and how to joinNCT05552157 - Phase 2/3Taking peopleA Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
- Where
- Québec, Toronto, Vancouver, Verdun
- Age
- 18 years and over
- People
- 280 worldwide
- Run by
- Washington University School of Medicine
See details and how to joinNCT06647498 - No phaseTaking peopleBrain Wave Informed Non-invasive Brain Stimulation: Improving Neural Networks of Working Memory in Dementia: a Proof-of-concept Study
- Where
- Hamilton
- Age
- 55 years and over
- People
- 30
- Run by
- McMaster University
See details and how to joinNCT07673770